Full text is available at the source.
Abstract
In a review of 33 trials involving 16,003 participants, once-weekly glucagon-like peptide 1 receptor agonists (GLP-1 RAs) demonstrated a reduction in glycated hemoglobin (HbA1c) of -0.66% with albiglutide and -1.18% with dulaglutide compared to placebo.
- Albiglutide and dulaglutide showed significant HbA1c reductions compared to placebo, with confidence intervals indicating variability in effectiveness.
- Dulaglutide outperformed other antidiabetic agents, achieving a greater mean HbA1c reduction than sitagliptin, daily exenatide, and insulin glargine.
- No significant weight-sparing benefits were observed for albiglutide or dulaglutide when compared to placebo.
- Common adverse effects included gastrointestinal issues and reactions at the injection site.
Simplified